Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab.
Benson
D M
DM
Smith
M K
MK
Krugh
D
D
Devine
S M
SM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications* / Q000188:drug therapy*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D012010:Red-Cell Aplasia, Pure / Q000209:etiology*; D012074:Remission Induction; D017701:Reticulocyte Count; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006454:Hemoglobins; D000069283:Rituximab